PCA for Skin

Besides An Essential Skin Care Ingredient, PCA Can Do More!

• 2024-06-13
  

  Sodium PCA in Skin Care | Detailed Guideline

  Sodium PCA's hydrating prowess lies in its capability to attract and keep moisture. As a humectant, it draws water molecules from the surroundings and the deeper layers of the pores and skin, developing a reservoir of hydration. This innate capability to hold in water makes sodium PCA in skin care a key player in stopping trans-epidermal water loss (TEWL), a not-unusual wrongdoer in dry and dehydrated pores and skin.
  sodium PCA in skin care
• 2024-08-27
  

  Verb Products Launches New Anti-Dandruff Shampoo

  Bridgette Hill, Certified Trichologist and Scalp Health Expert, said:“Verb’s introduction of an advanced yet affordable anti-dandruff shampoo truly fills a gap in the market, providing more options for consumers suffering from this common scalp condition. The brand’s passion and dedication to formulation excellence in launching this new category is impressive. Verb’s choice to invest in clinically tested, premium and effective ingredients like salicylic acid and zinc PCA reflects the brand’s value proposition of providing a best-in-class anti-dandruff product that both nourishes and repairs.”
  Verb Products Shampoo
• 2024-04-08
  

  Breakthroughs in Osimertinib and Three Other Investigational Drugs by Ascentage Pharma Revealed at AACR Annual Meeting

  Another noteworthy advancement presented by Ascentage Pharma at the AACR Annual Meeting focused on the synergistic inhibition of tumor growth in preclinical models of prostate cancer (PCa) through the combination of the embryonic ectoderm development (EED) inhibitor APG-5918 (EEDi-5273) and the MDM2 inhibitor alrizomadlin (APG-115). Prostate cancer is one of the most common malignancies in elderly males, and while androgen deprivation therapy (ADT) in combination with androgen receptor (AR) inhibitors is commonly used as an initial treatment for advanced PCa, most patients eventually develop castration-resistant prostate cancer (CRPC) and urgently require novel therapeutic approaches. Dysregulation of the polycomb repressive complex 2 (PRC2) is prevalent in PCa and is associated with poor prognosis. PRC2 mediates trimethylation of histone H3 lysine 27 (H3K27me3), an epigenetic mark that inhibits gene transcription. EED, a core component of PRC2, directly interacts with H3K27me3 and plays a crucial role in tumor growth.
• 2024-03-06
  

  Breakthrough Clinical Advances to be Unveiled by Ascentage Pharma at AACR 2024

  Ascentage Pharma' research also highlights the synergistic effects of the embryonic ectoderm development (EED) inhibitor APG-5918 and the MDM2 inhibitor alrizomadlin in preclinical models of prostate cancer (PCa). Through their regulation of DNA methylation, cell cycle progression, and apoptosis-related pathways, the combination of APG-5918 and APG-115 has demonstrated enhanced antitumor activity. These findings lay the groundwork for the clinical development of a combination therapy involving APG-5918 and APG-115 in the treatment of prostate cancer.
• 2023-01-18
  

  Cancer Res | new algorithm for decoding cancer's genetic ancestors

  The flow of genetic ancestry inference is shown in Figure 3, and the research team used a combination of principal component analysis (PCA) and K-nearest neighbor classification. For a subset of patients in each cohort, the research team evaluated the ancestry inference performance of the parameters K and D functions separately, and retained the number of primary dimensions to evaluate them based on data synthesis.
  pharmaceutical trend
• 2018-08-27
  

  Next steps for prostate cancer treatment

  What do KOLs think about other immunotherapy approaches including autologous dendritic cell (DC) therapies (e.g. DCVAC/PCA [stapuldencel-T; Sotio]) and viral-based therapies (e.g. ProstAtak [aglatimagene besadenovec; Advantagene])?